Investigate the activity and safety of adding Lu-PSMA to enzalutamide in patients with metastatic castrate resistant prostate cancer (mCRPC) not previously treated with chemotherapy.
Enzalutamide With Lu PSMA-617 Versus Enzalutamide Alone in Men With Metastatic Castration-resistant Prostate Cancer.
|Eligibility criteria|| |
|Study details|| |
Eligibility will be assessed based on screening GaPSMA PET and FDG PET. Once eligible you will be randomised to enzaluatamide alone or enzalutamide with LuPSMA. LuPSMA is a nuclear medicine targeted therapy. While on treatment there will be regular blood tests and scans to monitor progress. At completion of treatment the study will continue to follow your progress.
|Further information|| |
For more information regarding this clinical trial click here.
North Shore NSW